GRI
GRI Bio·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Gap Down
Significant Net Income Decline
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GRI
Gri Bio, Inc.
A clinical-stage biopharmaceutical company that develops novel drugs to deter abuse in the treatment of central nervous system disorders
2223 Avenida de la Playa, #208, La Jolla, CA 92037
--
GRI Bio, Inc. was incorporated under the laws of the State of Delaware on January 11, 2018. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for serious diseases associated with the dysfunctional immune response leading to inflammation, fibrosis and autoimmune diseases. The company's goal is to become an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
Company Financials
EPS
GRI has released its 2025 Q3 earnings. EPS was reported at -1.28, versus the expected -1.11, missing expectations. The chart below visualizes how GRI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
